We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+3.34%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$17.4B
AUM Growth
+$71.8M
Cap. Flow
-$218M
Cap. Flow %
-1.26%
Top 10 Hldgs %
90.2%
Holding
115
New
7
Increased
18
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$27.7M
2
ABCL icon
AbCellera Biologics
ABCL
+$26.2M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$23.1M
4
DNLI icon
Denali Therapeutics
DNLI
+$21.2M
5
GLUE icon
Monte Rosa Therapeutics
GLUE
+$12.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$63.1M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$55.9M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$48.1M
4
IMGN
Immunogen Inc
IMGN
+$28.7M
5
ANAB icon
AnaptysBio
ANAB
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.2%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRIX icon
26
Nurix Therapeutics
NRIX
$2.77B
$30.5M 0.18%
3,882,125
– –
BMEA icon
27
Biomea Fusion
BMEA
$99.3M
$29M 0.17%
2,108,949
– –
IDYA icon
28
IDEAYA Biosciences
IDYA
$3.83B
$28.7M 0.17%
1,062,123
– –
CERS icon
29
Cerus
CERS
$566M
$27.9M 0.16%
17,239,501
+1,171,943
+7% +$2.44M
JBIO
30
Jade Biosciences
JBIO
$1.36B
$26.6M 0.15%
56,099
– –
IGMS
31
DELISTED
IGM Biosciences
IGMS
$26.4M 0.15%
3,157,764
+554
+0% +$4.7K
XENE icon
32
Xenon Pharmaceuticals
XENE
$5.88B
$25.7M 0.15%
751,639
– –
CABA icon
33
Cabaletta Bio
CABA
$531M
$24.3M 0.14%
1,594,000
– –
GLUE icon
34
Monte Rosa Therapeutics
GLUE
$1.22B
$23.5M 0.14%
4,916,095
+1,892,144
+63% +$12.2M
DBVT
35
DBV Technologies
DBVT
$914M
$19.9M 0.11%
1,461,426
– –
KRYS icon
36
Krystal Biotech
KRYS
$10.3B
$19.7M 0.11%
169,934
– –
VERV
37
DELISTED
Verve Therapeutics
VERV
$18.8M 0.11%
1,416,530
– –
BCYC
38
Bicycle Therapeutics
BCYC
$306M
$17M 0.1%
843,814
– –
IMVT icon
39
Immunovant
IMVT
$9.16B
$16.3M 0.09%
+425,009
New +$9.61M
COGT icon
40
Cogent Biosciences
COGT
$6.37B
$12.6M 0.07%
1,292,966
+313,366
+32% +$3.72M
DAWN
41
DELISTED
Day One Biopharmaceuticals
DAWN
$12.3M 0.07%
1,000,000
– –
PRME icon
42
Prime Medicine
PRME
$615M
$9.81M 0.06%
1,028,466
– –
TSVT
43
DELISTED
2seventy bio
TSVT
$9.79M 0.06%
2,497,526
– –
RLAY icon
44
Relay Therapeutics
RLAY
$4.26B
$9.76M 0.06%
1,160,117
– –
PACB icon
45
Pacific Biosciences
PACB
$420M
$9.42M 0.05%
1,127,782
– –
INSM icon
46
Insmed
INSM
$27.5B
$8.66M 0.05%
343,000
– –
ADAP
47
DELISTED
Adaptimmune Therapeutics
ADAP
$8.56M 0.05%
10,969,282
– –
TNGX icon
48
Tango Therapeutics
TNGX
$4.03B
$8.45M 0.05%
750,000
– –
HRTX icon
49
Heron Therapeutics
HRTX
$60.4M
$8.38M 0.05%
8,131,678
– –
ARVN icon
50
Arvinas
ARVN
$613M
$8.12M 0.05%
+413,481
New +$10.1M
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2023 Portfolio in Review

As of Q3 2023, Julian Baker held 115 positions worth $17.4B, up 0.42% from $17.3B the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Julian Baker's Q3 2023 filing shows 7 new, 18 increased, 11 reduced and 14 closed positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M. The largest sale was argenx, an estimated $63.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q3 2023 buy was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M.
  • Julian Baker added most to Roivant Sciences in Q3 2023, an estimated $27.7M increase.
  • Julian Baker's biggest Q3 2023 reduction was argenx, cutting an estimated $63.1M.
  • Julian Baker fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $55.9M.
  • Julian Baker's ten largest holdings make up 90% of its $17.4B portfolio in Q3 2023.
  • Julian Baker opened 7 new positions and closed 14 in Q3 2023.
  • Julian Baker's portfolio value rose 0.42% quarter-over-quarter to $17.4B.

Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.